# Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension

> **NCT05968430** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Mineralys Therapeutics Inc.** · enrollment: 1076 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** lorundrostat
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05968430
- **Lead sponsor:** Mineralys Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-07-14
- **Primary completion:** 2025-12-30
- **Final completion:** 2026-12
- **Target enrollment:** 1076 (ACTUAL)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05968430

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05968430, "Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05968430. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*